Salta al contenuto
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Avanzata
  • Blast phase myeloproliferative...
  • Citazione
  • Invia SMS
  • Invia email
  • Stampa
  • Esporta il record
    • Esporta a RefWorks
    • Esporta a EndNoteWeb
    • Esporta a EndNote
  • PLink permanente
Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival

Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival

Dettagli Bibliografici
Autori principali: Maymona G. Abdelmagid, Aref Al-Kali, Kebede H. Begna, William J. Hogan, Mark R. Litzow, Farah Fleti, Abhishek A. Mangaonkar, Mrinal S. Patnaik, Michelle A. Elliott, Hassan Alkhateeb, Min Shi, Matthew T. Howard, Kaaren K. Reichard, Rhett P. Ketterling, Mithun Shah, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi
Natura: Articolo
Lingua:English
Pubblicazione: Ferrata Storti Foundation 2023-02-01
Serie:Haematologica
Accesso online:https://haematologica.org/article/view/10989
  • Posseduto
  • Descrizione
  • Documenti analoghi
  • MARC21

Accesso online

https://haematologica.org/article/view/10989

Documenti analoghi

  • Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor
    di: Naseema Gangat, et al.
    Pubblicazione: (2023-01-01)
  • Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant
    di: Ayalew Tefferi, et al.
    Pubblicazione: (2024-03-01)
  • Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients
    di: Abhishek A. Mangaonkar, et al.
    Pubblicazione: (2022-02-01)
  • CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases
    di: Rimal Ilyas, et al.
    Pubblicazione: (2023-02-01)
  • Targeted next-generation sequencing in blast phase myeloproliferative neoplasms
    di: Terra L. Lasho, et al.
    Pubblicazione: (2018-02-01)

Opzioni di ricerca

  • Ultime ricerche
  • Ricerca avanzata

Cerca

  • Scorri il catalogo
  • Scorri in ordine alfabetico
  • Esplora selezioni
  • Materiali riservati (per i corsi)
  • Nuovi documenti

Serve aiuto?

  • Suggerimenti per la ricerca
  • Chiedi al bibliotecario
  • FAQ